Showing 1–24 of 43 results

• 
  Early human evidence

  Acetyl Tetrapeptide-3

  £37.00
  10 mgBatch file pending

  Scalp/follicle matrix focus distinguishes it from SNAP-8’s expression-line mechanism and GHK-Cu’s copper biology.

  UnavailableAsk about availability
• 
  Early human evidence

  AOD-9604

  £32.49
  5 mgBatch file pending

  A GH-derived metabolic fragment—not an incretin, amylin analogue or GH secretagogue.

  Available · 10 in stockAdd to basket
• 
  Clinical research

  ARA-290 (Cibinetide)

  £72.00
  10 mgBatch file pending

  Separates tissue-protective EPO signalling from red-blood-cell production.

  UnavailableAsk about availability
• 
  Experimental

  Bronchogen

  £46.00
  20 mgBatch file pending

  Airway-tissue focus rather than VIP’s defined VPAC-receptor bronchodilatory biology.

  UnavailableAsk about availability
• 
  Clinical research

  Cagrilintide

  £64.00
  5 mgBatch file pending

  Targets amylin biology, making it mechanistically distinct from every incretin agonist in the category.

  UnavailableAsk about availability
• 
  Experimental

  Cartalax

  £46.00
  20 mgBatch file pending

  Cartilage-cell focus, rather than BPC-157’s broader repair signalling or GHK-Cu’s collagen/copper biology.

  UnavailableAsk about availability
• 
  Early human evidence

  CJC-1295 DAC

  £32.99 – £39.99Price range: £32.99 through £39.99
  5 mgBatch file pending

  Its albumin-binding extension creates sustained exposure, unlike CJC-1295 No DAC or sermorelin.

  Available · 10 in stockAdd to basket This product has multiple variants. The options may be chosen on the product page
• 
  Early human evidence

  CJC-1295 No DAC

  £25.99 – £32.99Price range: £25.99 through £32.99
  5 mgBatch file pending

  Short-duration GHRH signalling, in contrast with albumin-bound, long-acting CJC-1295 DAC.

  UnavailableAsk about availability This product has multiple variants. The options may be chosen on the product page
• 
  Experimental

  Dihexa

  £66.00
  10 mgBatch file pending

  HGF/c-Met synaptogenesis hypothesis, unlike Semax’s neurotrophic ACTH-fragment lineage.

  UnavailableAsk about availability
• 
  Early human evidence

  DSIP

  £13.99
  5 mgBatch file pending

  Sleep is its historical research label, but mechanistic certainty is much lower than for receptor-defined peptides.

  UnavailableAsk about availability
• 
  Experimental

  Endoluten

  £46.00
  20 mgBatch file pending

  Pineal/circadian branding with uncertain composition, distinct from sequence-defined Epithalon.

  UnavailableAsk about availability
• 
  Preclinical

  Epithalon

  £58.00
  10 mgBatch file pending

  A proposed pineal-derived bioregulator with telomere-focused claims, not a mitochondrial-targeting peptide.

  UnavailableAsk about availability
• 
  Experimental

  Follistatin 344

  £76.00
  1 mgBatch file pending

  A ligand-binding inhibitor of the activin/myostatin system, not a GH or IGF secretagogue.

  UnavailableAsk about availability
• 
  Preclinical

  FOXO4-DRI

  £92.00
  10 mgBatch file pending

  A targeted experimental senolytic mechanism, not a mitochondrial support or endocrine peptide.

  UnavailableAsk about availability
• 
  Early human evidence

  GHRP-2

  £44.00
  5 mgBatch file pending

  Typically characterised as a strong GH secretagogue with less appetite emphasis than GHRP-6.

  UnavailableAsk about availability
• 
  Early human evidence

  GHRP-6 Acetate

  £19.99 – £39.99Price range: £19.99 through £39.99
  5 mgBatch file pending

  Its prominent appetite/ghrelin research profile distinguishes it from the more selective ipamorelin.

  Available · 10 in stockAdd to basket This product has multiple variants. The options may be chosen on the product page
• 
  Early human evidence

  Hexarelin

  £51.00
  5 mgBatch file pending

  A potent older GHRP with less hormonal selectivity than ipamorelin.

  UnavailableAsk about availability
• 
  Preclinical

  Humanin

  £68.00
  10 mgBatch file pending

  Primarily cytoprotective/anti-apoptotic, whereas MOTS-c centres on metabolic stress signalling.

  UnavailableAsk about availability
• 
  Experimental

  IGF-1 DES

  £62.00
  1 mgBatch file pending

  A short-acting truncated analogue, contrasted with the extended long-exposure design of IGF-1 LR3.

  UnavailableAsk about availability
• 
  Experimental

  IGF-1 LR3

  £47.99
  1 mgBatch file pending

  Designed for longer, less binding-protein-restricted IGF signalling than native IGF-1 or IGF-1 DES.

  Available · 10 in stockAdd to basket
• 
  Early human evidence

  Ipamorelin

  £34.99 – £54.99Price range: £34.99 through £54.99
  5 mgBatch file pending

  A ghrelin-receptor secretagogue—not a GHRH analogue—and generally discussed as more selective than older GHRPs.

  Available · 20 in stockAdd to basket This product has multiple variants. The options may be chosen on the product page
• 
  Clinical research

  Kisspeptin-54

  £63.00
  5 mgBatch file pending

  Longer-lived isoform with direct human oocyte-maturation research, unlike the shorter kisspeptin-10.

  UnavailableAsk about availability
• 
  Preclinical

  KPV

  £27.47 – £29.99Price range: £27.47 through £29.99
  10 mgBatch file pending

  A minimal anti-inflammatory alpha-MSH fragment rather than an antimicrobial peptide such as LL-37.

  Available · 20 in stockAdd to basket This product has multiple variants. The options may be chosen on the product page
• 
  Experimental

  Livagen

  £46.00
  20 mgBatch file pending

  A liver-tissue bioregulator concept rather than a systemic metabolic receptor agonist.

  UnavailableAsk about availability